ClinicalTrials.gov
ClinicalTrials.gov Menu

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01269385
Recruitment Status : Unknown
Verified June 2015 by Mayo Clinic.
Recruitment status was:  Active, not recruiting
First Posted : January 4, 2011
Last Update Posted : April 21, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Mayo Clinic

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Actual Primary Completion Date : June 2014
  Study Completion Date : No date given

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 20, 2018
May 18, 2018